ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1
inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell
transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a
complete metabolic response (CMR) on FDG-PET-CT scan after 2 cycles of first or second line
salvage therapy.